vs
Side-by-side financial comparison of Astera Labs, Inc. (ALAB) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Astera Labs, Inc. is the larger business by last-quarter revenue ($270.6M vs $177.4M, roughly 1.5× Pacira BioSciences, Inc.). Astera Labs, Inc. runs the higher net margin — 16.6% vs 1.6%, a 15.0% gap on every dollar of revenue. On growth, Astera Labs, Inc. posted the faster year-over-year revenue change (91.8% vs 5.0%). Over the past eight quarters, Astera Labs, Inc.'s revenue compounded faster (103.6% CAGR vs -0.2%).
Astera Labs, Inc. is an American fabless semiconductor manufacturer and artificial intelligence company. The company specializes in designing high-speed connectivity solutions for data centers and AI infrastructure. The company has been listed on the Nasdaq since March 2024.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
ALAB vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $270.6M | $177.4M |
| Net Profit | $45.0M | $2.9M |
| Gross Margin | 75.6% | — |
| Operating Margin | 24.7% | 3.9% |
| Net Margin | 16.6% | 1.6% |
| Revenue YoY | 91.8% | 5.0% |
| Net Profit YoY | 82.0% | — |
| EPS (diluted) | $0.25 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $270.6M | $196.9M | ||
| Q3 25 | $230.6M | $179.5M | ||
| Q2 25 | $191.9M | $181.1M | ||
| Q1 25 | $159.4M | $168.9M | ||
| Q4 24 | $141.1M | $187.3M | ||
| Q3 24 | $113.1M | $168.6M | ||
| Q2 24 | $76.8M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $45.0M | — | ||
| Q3 25 | $91.1M | $5.4M | ||
| Q2 25 | $51.2M | $-4.8M | ||
| Q1 25 | $31.8M | $4.8M | ||
| Q4 24 | $24.7M | — | ||
| Q3 24 | $-7.6M | $-143.5M | ||
| Q2 24 | $-7.5M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | 75.6% | 79.5% | ||
| Q3 25 | 76.2% | 80.9% | ||
| Q2 25 | 75.8% | 77.4% | ||
| Q1 25 | 74.9% | 79.7% | ||
| Q4 24 | 74.0% | 78.7% | ||
| Q3 24 | 77.7% | 76.9% | ||
| Q2 24 | 77.9% | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 24.7% | 1.2% | ||
| Q3 25 | 24.0% | 3.5% | ||
| Q2 25 | 20.7% | 4.7% | ||
| Q1 25 | 7.1% | 1.2% | ||
| Q4 24 | 0.1% | 13.2% | ||
| Q3 24 | -7.9% | -82.8% | ||
| Q2 24 | -31.7% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | 16.6% | — | ||
| Q3 25 | 39.5% | 3.0% | ||
| Q2 25 | 26.7% | -2.7% | ||
| Q1 25 | 20.0% | 2.8% | ||
| Q4 24 | 17.5% | — | ||
| Q3 24 | -6.7% | -85.1% | ||
| Q2 24 | -9.8% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $0.25 | $0.05 | ||
| Q3 25 | $0.50 | $0.12 | ||
| Q2 25 | $0.29 | $-0.11 | ||
| Q1 25 | $0.18 | $0.10 | ||
| Q4 24 | $1.23 | $0.38 | ||
| Q3 24 | $-0.05 | $-3.11 | ||
| Q2 24 | $-0.05 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.6M | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.4B | $653.9M |
| Total Assets | $1.5B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $167.6M | $238.4M | ||
| Q3 25 | $140.4M | $246.3M | ||
| Q2 25 | $162.3M | $445.9M | ||
| Q1 25 | $86.4M | $493.6M | ||
| Q4 24 | $79.6M | $484.6M | ||
| Q3 24 | $126.1M | $453.8M | ||
| Q2 24 | $421.1M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $1.4B | $693.1M | ||
| Q3 25 | $1.3B | $727.2M | ||
| Q2 25 | $1.1B | $757.8M | ||
| Q1 25 | $1.0B | $798.5M | ||
| Q4 24 | $964.8M | $778.3M | ||
| Q3 24 | $889.6M | $749.6M | ||
| Q2 24 | $845.3M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $1.5B | $1.3B | ||
| Q3 25 | $1.4B | $1.3B | ||
| Q2 25 | $1.3B | $1.5B | ||
| Q1 25 | $1.1B | $1.6B | ||
| Q4 24 | $1.1B | $1.6B | ||
| Q3 24 | $983.1M | $1.5B | ||
| Q2 24 | $915.5M | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $95.3M | — |
| Free Cash FlowOCF − Capex | $76.6M | — |
| FCF MarginFCF / Revenue | 28.3% | — |
| Capex IntensityCapex / Revenue | 6.9% | — |
| Cash ConversionOCF / Net Profit | 2.12× | — |
| TTM Free Cash FlowTrailing 4 quarters | $281.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $95.3M | $43.7M | ||
| Q3 25 | $78.2M | $60.8M | ||
| Q2 25 | $135.4M | $12.0M | ||
| Q1 25 | $10.5M | $35.5M | ||
| Q4 24 | $39.7M | $33.1M | ||
| Q3 24 | $63.5M | $53.9M | ||
| Q2 24 | $29.8M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $76.6M | $43.5M | ||
| Q3 25 | $65.9M | $57.0M | ||
| Q2 25 | $133.3M | $9.3M | ||
| Q1 25 | $6.0M | $26.9M | ||
| Q4 24 | $24.3M | $31.0M | ||
| Q3 24 | $46.8M | $49.8M | ||
| Q2 24 | $28.5M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | 28.3% | 22.1% | ||
| Q3 25 | 28.6% | 31.7% | ||
| Q2 25 | 69.5% | 5.1% | ||
| Q1 25 | 3.7% | 15.9% | ||
| Q4 24 | 17.2% | 16.6% | ||
| Q3 24 | 41.4% | 29.6% | ||
| Q2 24 | 37.1% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 6.9% | 0.1% | ||
| Q3 25 | 5.3% | 2.2% | ||
| Q2 25 | 1.1% | 1.5% | ||
| Q1 25 | 2.8% | 5.1% | ||
| Q4 24 | 10.9% | 1.1% | ||
| Q3 24 | 14.8% | 2.4% | ||
| Q2 24 | 1.7% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | 2.12× | — | ||
| Q3 25 | 0.86× | 11.20× | ||
| Q2 25 | 2.64× | — | ||
| Q1 25 | 0.33× | 7.37× | ||
| Q4 24 | 1.61× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ALAB
Segment breakdown not available.
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
